Beacon NewsFlashes – January 14, 2013
HHV-6 Infection May Be Common After Stem Cell Transplantation – Results of a retrospective Israeli study indicate that human herpesvirus 6 (HHV-6) infection is common in multiple myeloma patients after...
View ArticleShort-Term Velcade-Based Combination Therapies May Be Effective And Safe For...
Results from a recent, small-scale study conducted at the MD Anderson Cancer Center in Houston suggest that three Velcade-based combination therapies given at lower doses over a short period of time...
View ArticleBeacon NewsFlashes – February 4, 2013
SF1126 Shows Promise As A Treatment Option For Myeloma Patients – Findings from a preclinical study suggest that the Semafore Pharmaceuticals’ investigational drug SF1126 may have anti-myeloma activity...
View ArticleVelcade-Based Therapy May Improve Outcomes For Myeloma Patients Who Do Not...
Results of a small Phase 2 study may lead to improved outcomes for newly diagnosed patients who are unable to achieve a deep response with a Revlimid- or thalidomide-based initial therapy. The study...
View ArticleVelcade-Dexamethasone Plus Donor Lymphocyte Infusions In Myeloma Patients...
Results from a small Italian Phase 2 clinical trial indicate that Velcade plus dexamethasone, followed by donor lymphocyte infusions, may be an important treatment option for patients who relapse after...
View ArticleBeacon NewsFlashes – March 11, 2013
Treanda May Enhance Response To Stem Cell Transplant In Myeloma Patients – Results from a Phase 1 clinical trial demonstrate the safety of adding Treanda (bendamustine) to melphalan (Alkeran) as...
View ArticleLetters From Cancerland: The Velcade Velocipede
Velcade is my velocipede. Velocipedes were all the rage in post-Civil War America. Known also as “boneshakers” for the rough physical treatment these early bicycles gave their riders, they proved...
View ArticleAdvanced Age And Organ Damage Associated With Poor Survival In Elderly...
A team of European researchers recently found that advanced age, kidney failure, infections, heart and gastrointestinal complications, and drug discontinuation are associated with poor survival among...
View ArticleBeacon NewsFlashes – April 15, 2013
Velcade-Thalidomide-Dexamethasone Combination May Be Effective After A Stem Cell Transplant In Multiple Myeloma Patients – Results from a French study show that the combination of Velcade (bortezomib),...
View ArticleVelcade Consolidation Therapy After Stem Cell Transplantation May Improve...
Results from a recent European Phase 3 clinical trial indicate that a few months of treatment with Velcade may improve the outcomes of multiple myeloma patients who recently underwent a stem cell...
View ArticleThe European Hematology Association’s Annual Congress Starts Today: A Look At...
Physicians and researchers have started gathering for the 18th Congress of the European Hematology Association (EHA), which will take place in Stockholm this year. The first education and poster...
View ArticleSequential Treatment With Novel Agents Is Effective And Safe In Older, Newly...
Results from a small Phase 2 study conducted in Italy demonstrate that sequential treatment with novel agents and autologous stem cell transplantation with intermediate-dose melphalan is a...
View ArticleOlder Myeloma Patients Treated With Novel Agents May Be At Increased Risk For...
Researchers at the Medical College of Wisconsin recently found that multiple myeloma patients are at an increased risk of engraftment syndrome following stem cell transplantation, compared to...
View ArticleBeacon NewsFlashes – July 15, 2013
Revlimid Plus Dexamethasone Extends Progression-Free Survival In Newly Diagnosed Multiple Myeloma Patients – Results of a large international Phase 3 trial show that Revlimid (lenalidomide) plus...
View ArticleVelcade Before And After Donor Stem Cell Transplantation May Improve The...
Results from a recent small Phase 3 clinical trial show that the use of Velcade in preparation for donor stem cell transplantation as well as its use soon after transplantation and as maintenance...
View ArticleVelcade, Doxorubicin, And Intermediate-Dose Dexamethasone May Be Effective In...
Results from a small Phase 2 study conducted throughout Japan suggest that a combination of Velcade, doxorubicin, and intermediate-dose dexamethasone is effective in patients with relapsed or...
View ArticleBeacon NewsFlashes – August 12, 2013
Velcade Receives Additional Approvals In Europe – The approved uses of Velcade (bortezomib) for multiple myeloma patients were recently expanded in the European Union. These additional approved uses...
View ArticleItalian Study Documents Efficacy And Safety Of Velcade Plus Dexamethasone In...
A new study provides useful, if somewhat dated, insight into the efficacy and safety of Velcade combined with dexamethasone to treat relapsed or refractory multiple myeloma. The retrospective study,...
View ArticleKyprolis Or Pomalyst For Dual-Refractory Myeloma - What Is The Survival Impact?
A new retrospective study provides insight into the benefit the new myeloma drugs Kyprolis and Pomalyst may provide to patients who are resistant to, or cannot tolerate, both Velcade and Revlimid....
View ArticlePanobinostat-Velcade-Dexamethasone Combination Continues To Show Promise For...
Final results from a recent Phase 2 clinical trial continue to indicate that panobinostat in combination with Velcade and dexamethasone is effective for heavily pretreated multiple myeloma. In the...
View Article
